Loading...
A vaccine for the prevention of cervical, vulvar, and perineal lesions caused by four human papillomavirus (HPV) serotypes is approved for administration to females from ages 9 to 26, when incidence of HPV infection peaks.
In an international, manufacturer-sponsored trial, 3819 nonpregnant women between the ages of 24 and 45 with intact uteri and no history of genital warts or cervical disease were randomized to receive doses of quadrivalent HPV vaccine or placebo at 0, 2, and 6 months. At baseline, 30% of women had antibodies to at least one vaccine HPV serotype, and 8% had DNA from at least one vaccine HPV serotype on swabs of the vulva, perineum, and cervix.
Within 7 months, 97% to 99% of women who completed the vaccine regimen seroconvert…